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An antibody against basic fibroblast growth factor (bFGF) was raised using purified bovine pituitary bFGF. Western blot analysis revealed im- 
munoreactive. bands at 18,24, 30-33 and 46 kDa in immunoaffinity purified extracts of pituitary and adrenal gland using this antibody. A similar 
staining pattern was obtained with ovary extracts with the exception of the missing 18 kDa band. A second anti-bFGF antibody raised against 
a synthetic peptide comprising the 24 N-terminal amino acids of bFGF reacted with the 18 kDa and the 46 kDa band of immunoaffinity purified 
ovary and ad&al gland extracts. 
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1. INTRODUCTION 
Basic fibroblast growth factor (bFGF) is an 
angiogenic factor and a mitogen for many mesoderm- 
derived cells [ 11. In addition, bFGF also influences pro- 
liferation and differentiation of glial cells [2,3]. Recent- 
ly, in vivo and in vitro studies have shown that bFGF 
exerts neurotrophic actions in the peripheral (PNS) and 
central nervous system (CNS) [4-g]. Basic FGF has 
been purified from various tissues including brain, 
pituitary, corpus luteum, placenta, adrenal gland, 
kidney, and thymus (for reviews see [l,lO]). 
To further investigate the physiolbgical role of bFGF 
immunological studies using antibodies against bFGF 
are a useful tool to elucidate: (i) the cellular and 
subcellular localization of bFGF in tissues from which 
bFGF can be isolated [ 11,121; (ii) the developmental ex- 
pression of bFGF in the CNS and PNS; (iii) the 
presence of bFGF in various tissues, cells and extracts 
with neurotrophic activity [ 12,131. 
Basic FGF is a polypeptide of 146 residues. Tissue- 
and species-specific forms were found to originate from 
N-terminal truncation due to proteolysis that results in 
molecular masses between 16 and 18 kDa (for review 
see [lo]). So far, higher molecular mass forms of bFGF 
have been isolated from guinea pig brain (25 kDa) [14] 
and rat brain (22 kDa) [IS]. Immunological studies of 
Presta and co-workers [16] revealed immunoreactive 
bFGF-like proteins of 27 and 29 kDa in addition to the 
18 kDa bFGF. The biological function of these high 
molecular weight forms remains to be resolved. 
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Here we describe a polyclonal antibody against the 
bovine pituitary bFGF, which, in addition to the 
described immunoreactive bFGF-like proteins [ 161, 
recognizes a 46 kDa protein with putative neurotrophic 
activity. 
2. MATERIALS AND METHODS 
2.1. Anti-bFGF antiserum 
New Zealand white rabbits were immunized with 130 pg aliquots 
of purified bovine pituitary bFCiF (generous gift of IX 
Gospodarowicz). Two subcutaneous injections (1st week in Freund’s 
complete adjuvant, 3rd week in incomplete adjuvant) were followed 
by 3 intravenous injections (4th, 5th and 10th week). Antibody titers 
were determined from enzyme-linked immunosorbent assay (ELISA) 
[17]. %-well microtiter plates were coated with bFGF (20 nglwell), 
reacted with the antiserum, peroxidase-conjugated goat anti-rabbit 
IgG (Sigma) and o-phenylendiamine as a chromogen. IgG-fractions 
were purified by ammonium sulfate precipitation [18]. This antibody 
will be referred to as anti-bFGFb,. An antibody (generous gift of P. 
Bdhlen and A. Baird) against a synthetic peptide comprising the 24 
N-terminal amino acids of bFGF (anti-bFGFN.& was also used. 
2.2 Affinity chromatography and Western blot analysis 
For enrichment of bFGF, bovine tissues (adrenal gland, ovary and 
pituitary) were extracted with 150 mM ammonium sulfate. Proteins 
precipitating between 1.9 and 3.8 M ammonium sulfate [19] were 
loaded onto an affinity column with anti-bovine bFGF IgG covalent- 
iy bound to CNBr-activated Sepharose [20]. After elution of bound 
material with 2 M NaCl in phosphate buffer (IO mM, pH 7) or distiil- 
ed water followed by NaCVphosphate buffer, proteins were 
separated by sodium dodecyl sulfate (SDS) polyacrylamide gel- 
electrophoresis (PAGE) [21]. Following electrophoretic transfer onto 
nitroceilulose or immobilon (Millipore), anti-bFGF immunoreactive 
bands were visualized using the ~roxidase-anti~oxidase method 
and diaminobenzidine as a chromogen. Control Western blots were 
developed without firstly using anti-bFGF antibody. In most cases 
immunoblotting on immobilon gave better results compared to 
nitrocellulose in terms of background staining and sharpness of 
bands. 
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Fig.1. Silver stain of a 15% SDS-PAGE gel (left side) and Western 
blot analysis (right side) of acidic (A; 1.5 rg) and basic FGF (B; 1 pg) 
probed with anti-bFGFb, antibody. 
2.3. Bioassay 
Neurotrophic activity of bFGF-enriched fractions was tested in a 
bioassay using chick ciliary ganglionic neurons of embryonic day 8 
(cCG 8) [6]. To establish plateau survival values we used saturating 
concentrations of purified or recombinant bovine bFGF [6] (recombi- 
nant bFGF was kindly provided by PROGEN, Heidelberg) or CNTF- 
containing cell-free extracts from selected embryonic hick eye tissues 
(CIPE) (221. Culture medium without trophic factors served as the 
baseline control. 
3. RESULTS 
3.1. Characterization of the anti-bFGFb, and antigens 
We first established that the antiserum against 
bFGFt,, was specific in that it did not crossreact with 
acidic FGF (fig. I), a protein comprising about 50% se- 
quence homology to bFGF [lo]. Antibody titer (1:400, 
fig.2) as well as the detection limit (5-10 ng bFGF at a 
1:50 dilution, fig.3) were obtained from ELISAs. 
Western blot analysis of several crude tissue extracts 
with anti-bFGFb, antiserum revealed no reactivity at 
all, or very weak reactivity with a 46 kDa polypeptide. 
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Fig.2. ELISA of anti-bFGFb, antibody (closed circles) and preim- 
mune serum (open circles) on bFGF-coated microtiter plates (20 
pg/well). 
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Fig.3. ELISA of anti-bFGFb, antibody (1:50 diluted) on bFGF- 
coated or control (dashed line; without antigen or coated with 2% 
BSA in PBS) microtiter plates. 
Thus, for all further experiments extracts enriched in 
bFGF by ammonium sulfate precipitation [19] and 
anti-bFGFb, affinity chromatography were used. In 
such extracts from bovine pituitary and adrenal gland, 
besides the previously reported 18 kDa bFGF, further 
immunoreactive bands of about 24, 30-33 and 46 kDa 
were observed (fig.4). A similar staining pattern was 
obtained with ovary extracts; however, the 18 kDa 
band was virtually absent (fig.4). 
We also subjected the bFGF-enriched extracts to 
Western blot analysis with anti-bFGFN_24. This an- 
tibody also detected both, the 18 kDa and the 46 kDa 
band in bovine adrenal gland (fig.4) as well as ovary 
(fig.5). 
3.2. Neurotrophic activity of affinity-enriched bFGF 
fractions 
Fractions from bovine ovary containing the 18 as 
A B C D 
Fig.4. Western blot analysis of immunoaffinity purified extracts of 
pituitary (A; 50 rg), ovary (B; 50 pg), and adrenal gland (C and D; 
100 l(g) probed with anti-bFGFb, (A, B, C) and anti-bFGFN.24 an- 
tibody (D), respectively. 
36 
Volume 260, number 1 FEBS LETTERS January 1990 
-46 
-24 
-18 
BA BA 
Fig.5. Western blot analysis of immunoaffinity purified extracts of 
ovary probed with anti-bFGFs, (left side) and anti-bFGFa.24 (right 
side): (A) distilled water peak (100 pg); (B) NaCl peak (100 pg). 
well as the 46 kDa immunoreactive bands were found 
to promote neuronal survival. Using a two-step elution 
from the anti-bFGFb, column with distilled water as the 
first and NaCl as the second eluant, we were able to 
separate the 46 kDa (water peak) from the 18 kDa 
(NaCl peak) band (fig.5). Both eluants exhibited com- 
parable neurotrophic activities (ED50 of 46 kDa frac- 
tion = 0.8 pg/ml: EDso of kDa fraction = 1.8 pg/ml) 
(fig.6). 
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4. DISCUSSION 
We have demonstrated here that, in addition to the 
18 kDa bFGF, higher molecular weigth forms exist in 
bovine tissues which are immunologically related to 
bFGF. Heparin-binding growth factors (HBGF) with 
molecular masses of 16-18 kDa have been isolated 
from a variety of tissues. These proteins seem to be 
closely related or identical to bFGF (for review see 
[lo]). It is conceivable that the sequences of HBGFs, in- 
cluding those of higher molecular weights, contain con- 
served heparin-binding and receptor-binding domains 
but may differ with respect to extensions at the N- 
terminus and/or glycosylation [lo]. In addition, studies 
of cDNA clones of bFGF showing an open reading 
frame extending beyond the 5 ’ end suggested that 
bFGF may be synthesized initially as a precursor [23] 
and that different bFGF forms might derive from 
processing of a precursor protein. Two high molecular 
mass forms of bFGF have been isolated so far which 
exist in addition to the 18 kDa bFGF in the respective 
tissues [14,15]. 
At present, 3 different antisera against bFGF (fig.3 
in [la] and this study) have been characterized that 
recognize immunoreactive bFGF bands of a molecular 
mass of about 46 kDa. The finding that 18 kDa bFGF 
in ovary extracts is detected by the anti-bFGFN_B, but 
not by the anti-bFGFb, antiserum, might reflect the 
presence of an ovary-specific 18 kDa bFGF whose do- 
mains for the latter antiserum are absent or masked. 
The relatively high protein concentrations necessary 
for detection of neurotrophic activities could result 
from a loss of biological activity after immunoaffinity 
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Fig.6. Representative dose-response curves on cCG 8 neurons of water peak and NaCl peak after immunoaffinity chromatography of ovary ex- 
tracts. 
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enrichment or from impurities. However, cell blot 
analysis of medullary extract enriched for bFGF in the 
same way revealed neurotrophic activities at the respec- 
tive molecular weights [12]. 
We conclude that besides the typical 16-18 kDa 
bFGF several tissues may additionally contain higher 
molecular weight forms of bFGF with putative 
,biological activity. 
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